Searchable abstracts of presentations at key conferences in endocrinology

ea0037s19.2 | Metabolic dysfunction in PCOS | ECE2015

The role of androgens in PCOS-related insulin resistance

O'Reilly Michael , Tomlinson Jeremy , Semple Robert , Arlt Wiebke

Insulin resistance and androgen excess are the cardinal features of polycystic ovary syndrome (PCOS). The severity of hyperandrogenism and metabolic dysfunction in PCOS are closely correlated but the underlying mechanisms are poorly understood. Aldoketoreductase type 1C3 (AKR1C3) is an important source of adipose androgen generation (converting androstenedione to testosterone) and we have postulated that it may have a critical role linking androgen metabolism and meta...

ea0065oc5.3 | Adrenal and Cardiovascular | SFEBES2019

Common variants in the gene encoding corticosteroid binding globulin influence cortisol-responsive gene networks in human adipose tissue

Bankier Sean , Crawford Andrew , Wang Lingfei , Bjorkegren Johan , Andrew Ruth , Walker Brian R , Michoel Tom

A genome wide meta-analysis by the CORtisol NETwork (CORNET) consortium1 has identified genetic variants spanning the SERPINA6/SERPINA1 locus on chromosome 14 associated with changes in morning plasma cortisol and predictive of cardiovascular disease (Crawford et al, Unpublished). SERPINA6 encodes Corticosteroid Binding Globin (CBG) which binds most cortisol in blood and influences delivery of cortisol to target tissues. We hypothesised th...

ea0037oc5.4 | Steroids, developmental and paediatric endocrinology | ECE2015

Adipose tissue-specific androgen generation fuels an adverse metabolic phenotype in patients with polycystic ovary syndrome

O'Reilly Michael , Kempegowda Punith , Gathercole Laura , Taylor Angela , Bujalska Iwona , Tomlinson Jeremy , Arlt Wiebke

Insulin resistance and androgen excess are the cardinal features of polycystic ovary syndrome (PCOS). The severity of hyperandrogenism and metabolic dysfunction in PCOS are closely correlated, but underlying mechanisms remain poorly understood. Aldoketoreductase type 1C3 (AKR1C3) is an important source of adipose androgen generation, activating androstenedione to testosterone (T). We postulated that AKR1C3 plays a critical role linking androgen metabolism and...

ea0055wa6 | Workshop A: Disorders of the hypothalamus and pituitary (I) | SFEEU2018

Primary CNS lymphoma as a cause of diabetes insipidus

Gilroy Michael

A 38 female patient with a diagnosis of primary CNS lymphoma was admitted for MATRIX (methotrexate, rituximab, thiopeta, cytarabine) chemotherapy. Prior to chemotherapy and while on steroids she became increasingly polydipsic and polyuric with blood biochemistry demonstrating a sodium of 164 mmol/l. An endocrine review of the patient was requested and a diagnosis of cranial diabetes insipidus was suspected due to the extent of infiltration of the hypothalamus and pituitary sta...

ea0051en1.1 | (1) | BSPED2017

Skeletal dysplasias-diagnosis, management and prospects for future therapies

Wright Michael

The skeletal dysplasias or genetic skeletal disorders (GSDs) are a heterogeneous group of over 450 conditions associated with varying degrees of disproportionate short stature. The diagnosis of these conditions has relied on a combination of clinical and radiographic assessment. The original classifications of the GSDs was based on x-ray imaging, but Spranger and others predicted that there would be ‘families’ of GSDs with the same underlying molecular basis. The adv...

ea0081s8.3 | Trace elements in endocrinology: too low or too high | ECE2022

Iron and the thyroid

Zimmermann Michael

Despite significant progress, deficiencies of iron and iodine remain major public health problems affecting >30% of the global population. These deficiencies often coexist in populations. Iron deficiency has adverse effects on thyroid metabolism. Iron deficiency impairs thyroid hormone synthesis by reducing activity of heme-dependent thyroid peroxidase. Iron-deficiency anemia blunts, and iron supplementation improves the efficacy of iodine supplementation. Studies have dem...

ea0081ecas1.4 | Europe needs more endocrinology | ECE2022

Laboratory chaos diverted – the case of the in vitro diagnostics regulation

Vogeser Michael

In vitro diagnostics (IVD) in the European Union is facing a fundamental change with the introduction of a new regulation, the so-called In Vitro Diagnostics Regulation (IVDR). Originally, the IVDR was scheduled to enter into force in May 2022, however, in January 2022, the EU legislator made a differentiated partial postponement of the application of important parts of the IVDR. The major innovation and achievement of the IVDR is that most commercially manufactured IVD produc...

ea0086hdi2.3 | How do I...? 2 | SFEBES2022

How do I choose an oral contraceptive for my patient with PCOS?

O'Reilly Michael

This talk will focus on contraceptive options for patients with polycystic ovary syndrome (PCOS). Key considerations for clinicians will be explored, including the choice of appropriate formulations for cycle regulation, control of symptoms of androgen excess and suppression of dysfunctional menstrual bleeding. Other issues covered during this session will include contraceptive options in patients with obesity or at high risk of complications such as venous thromboembolism, as...

ea0091cb49 | Additional Cases | SFEEU2023

Cushing’s Disease during the COVID Lockdown

Gilroy Michael

A 36-year-old female was referred to Endocrinology by her GP in August 2019 with polycythaemia, obesity, hypertension, type 2 diabetes, asthma, right shoulder and bilateral ankle pain [on 6-monthly steroid injections], easy bruising, hirsutism, PCOS and raised testosterone. Haematology had excluded likely causes of polycythaemia [JAK 2 negative]. The GP noted previous review by Endocrinology in another hospital [December 2012] regarding possible PCOS but was lost to follow up ...

ea0063s23.2 | PCOS: can we personalise treatment? | ECE2019

Implicating androgen excess in metabolic disease in PCOS

O'Reilly Michael

Insulin resistance and androgen excess, alongside anovulatory infertility, are the cardinal clinical and biochemical features of polycystic ovary syndrome (PCOS). Circulating androgen burden and metabolic dysfunction in PCOS are closely correlated, but an independent contribution of androgens perseto metabolic and other complications of PCOS remains poorly characterised. My work focuses on delineating the distinct impact of androgens on metabolic function, with a part...